Published by
@ShahidNShah
@ShahidNShah
April 15 to April 16, 2021
Las Vegas, Nevada, United States
A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented. At the conclusion of this course, participants will be able to: - Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with a specific focus on DOTA, PSMA, and PRRT - Describe the logistics of bringing these new diagnostic and therapeutic technologies to clinical practice - Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging - Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era.
Continue reading at ektron.rsna.org
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Nov 5, 2024 at 4:53am